Clinical Trial Update: A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inclisiran for Homozygous Familial Hypercholesterolemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Homozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2022-11-10